What is it about?
Post-marketing study of nivolumab for recurrent or metastatic head and neck cancer in Japan
Featured Image
Why is it important?
This study showed the clinical data of nivolumab for RMHNC in clinical practice
Read the Original
This page is a summary of: Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance, International Journal of Clinical Oncology, June 2021, Springer Science + Business Media,
DOI: 10.1007/s10147-021-01949-1.
You can read the full text:
Contributors
The following have contributed to this page
